KRTX Company Profile and Key Details

Q: Who are the executives of KRTX?

Dr. Troy A. IgnelziChief Financial Officer & Sec.Mr. Jason Parker BrownChief Financial OfficerDr. Steven M. Paul M.D.Pres of R&D, Chief Scientific Officer & DirectorMs. Charmaine LykinsChief Commercial OfficerMr. Jonathan RosinChief HR OfficerDr. Stephen K. BrannanChief Medical OfficerDr. Ronald N. Marcus M.D.Senior Vice President of MedicalMr. William MeuryPres, Chief Executive Officer & DirectorMr. William P. Kane Jr.Chief Commercial OfficerMs. Mia Kelley J.D.Vice President of Legal AffairsDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorMs. Stephanie MooreVice President of HRDr. Andrew Craig MillerCo-Founder & Chief Operating Officer

NASDAQ : KRTX

Karuna Therapeutics

$329.83

0.09+0.03%

At Close 4:00 PM

Not Actively Trading

74.07

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Karuna Therapeutics, Inc. (KRTX) stock surged +0.03%, trading at $329.83 on NASDAQ, up from the previous close of $329.74. The stock opened at $329.75, fluctuating between $329.75 and $329.97 in the recent session.

Stock Snapshot

329.74

Prev. Close

12.6B

Market Cap

329.75

Day Low

-28.094548551959114

P/E Ratio

-11.74

EPS (TTM)

-10.29

Cash Flow per Share

329.75

Open

38.2M

Number of Shares

329.97

Day High

94.94%

Free Float in %

33.2

Book Value

1.28M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 18, 2024	329.83	329.83	329.83	329.83	0
Mar 15, 2024	329.75	329.99	329.75	329.83	1.87M
Mar 14, 2024	329.76	329.80	329.61	329.74	3.39M
Mar 13, 2024	322.46	323.78	320.94	321.98	674.78K
Mar 12, 2024	319.60	322.32	319.46	322.32	659.01K
Mar 11, 2024	319.11	320.35	318.52	319.19	210.53K
Mar 08, 2024	317.80	319.95	317.53	319.95	345.96K
Mar 07, 2024	319.39	319.66	317.07	317.45	241.74K
Mar 06, 2024	318.22	319.85	316.77	318.41	252.79K
Mar 05, 2024	318.24	319.31	317.62	318.83	156.94K
Mar 04, 2024	315.58	318.38	315.58	318.24	188.54K
Mar 01, 2024	315.00	317.00	314.30	316.24	242.65K
Feb 29, 2024	315.84	316.46	313.89	313.97	350.52K
Feb 28, 2024	314.53	316.73	314.53	315.55	122.34K
Feb 27, 2024	315.77	318.40	314.35	314.89	313.95K
Feb 26, 2024	319.90	320.33	296.06	315.99	1.11M
Feb 23, 2024	318.62	320.56	318.62	320.25	339.89K
Feb 22, 2024	318.94	319.62	318.40	319.38	375.09K
Feb 21, 2024	318.01	319.00	318.01	318.94	255.99K
Feb 20, 2024	317.75	319.00	317.56	318.59	350.17K

Contact Details

Boston, MA 02110

United States

https://www.karunatx.com 857 449 2244

About Company

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.43-1.09%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Karuna Therapeutics, Inc. (NASDAQ:KRTX) closed at $329.83 USD, gaining $0.09 (0.03%) from the previous close of $329.74. The stock is currently trading near its 52-week high $158.38 and $329.99. With a market capitalization of about $12.60 billion, Karuna Therapeutics, Inc. is classified as a large-cap and shows market-like volatility (beta ~1.15). Key stats such as the average daily volume over the past year has been around 971.83 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Karuna Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William Meury, the company employs approximately 339 people and listed since June 28, 2019. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.27%, SMA50 3.92%, SMA200 44.47%). The stock’s 14-day RSI is 75.4 (overbought), while the ATR of 3.32 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -0.05% below its high and over 108.26% above its low.

Valuation Metrics

Karuna Therapeutics, Inc. trades at a P/E ratio of -28.11, slightly below the S&P 500 average, with a price-to-sales ratio of 19264.95 and a price-to-book ratio of 9.72 trading at moderately above to book value. The P/FCF stands at -32.41, also below market averages.

Dividend & Fair Value

Karuna Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.56. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Karuna Therapeutics, Inc. generated EPS of -$10.93 over the past year. Five-year average earnings growth is -102.34%. The latest quarter delivered EPS of -$2.80. The next quarter is forecast at -$2.69. Next year's EPS is expected at $1.78. Karuna Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 02, 2024, missed forecasts by -6.67%. The prior quarter beat by 14.02%. Over the last six quarters, Apple has recorded several small beats. These include -1.33% in February 23, 2023.

Shareholding & Insider Activity

Karuna Therapeutics, Inc. has 38.20 million shares outstanding. The public float is 36.27 million shares, elevated short interest at 6.03% of float. This equals 1.97 million shares. The short ratio is 3.6 days. Institutional investors hold 90.85% of the float. Insiders own 4.99%. Brannan Stephen K. holds 42.60 thousand shares, Ignelzi Troy A. has 30.49 thousand shares and Miller Andrew Craig has 24.40 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Karuna Therapeutics generated $654.00K in revenue, or $0.02 per share. Gross margin was -160.09%, operating margin -75653.98%, and net profit margin -66311.93%. Returns are negative, with ROA at -32.46% and ROE at -34.58%.
On valuation metrics, Karuna Therapeutics trades at a P/E of -28.11, P/S of 19264.95 and P/B of 9.72. The current ratio is 19.31 and quick ratio is 18.82. Operationally, the company’s inventory turnover is 0.05 and cash conversion cycle is 8324.08 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -23.12.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Karuna Therapeutics posted revenue of $654.00K, down slightly from $10.64M in the prior quarter. Gross profit was - $1.05M (margin -160.09%). Operating income was - $494.78M (margin -75654.0%). Net income was- $433.68M (EPS - $11.73).
The company ended the quarter with $1.26B in cash and short-term investments, a total debt of $16.69M, and net debt of - $169.14M. Total assets were $1.34B, with equity of $1.25B. Financials further reflected weakness, with operating cash flow of - $385.82M, free cash flow of - $388.74M, and capital expenditures of - $2.92M.

Price Forecast & Outlook

Our AI price prediction model suggests that Karuna Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.67%, with price expected at $345.22 by April 01, 2024, within a range of $340.84 to $349.63 3-Month Outlook: Projected rise of 114.26%, reaching $706.71 by June 14, 2024, with a range of $703.06 to $710.35. 1-Year Outlook: Projected gain of 111.14%, with price at $696.41 by March 18, 2025, within a range of $682.04 to $710.99.

Key Takeaways

Karuna Therapeutics, Inc. (NASDAQ:KRTX) shares are flat 0.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Karuna Therapeutics, Inc. trading at a premium to the broader market with a P/E of -28.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $215.78, suggesting -34.58% downside. Our AI forecast model points to short-term strength (4.67% over two weeks), a medium-term rise (114.26% over three months), and a longer-term gain (111.14% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Karuna Therapeutics, Inc. (KRTX) stock price?

Karuna Therapeutics, Inc. (NASDAQ: KRTX) stock price is $329.83 in the last trading session. During the trading session, KRTX stock reached the peak price of $329.97 while $329.75 was the lowest point it dropped to. The percentage change in KRTX stock occurred in the recent session was 0.03% while the dollar amount for the price change in KRTX stock was $0.09.

KRTX's industry and sector of operation?

The NASDAQ listed KRTX is part of Biotechnology industry that operates in the broader Healthcare sector. Karuna Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KRTX?

Dr. Troy A. Ignelzi
Chief Financial Officer & Sec.
Mr. Jason Parker Brown
Chief Financial Officer
Dr. Steven M. Paul M.D.
Pres of R&D, Chief Scientific Officer & Director
Ms. Charmaine Lykins
Chief Commercial Officer
Mr. Jonathan Rosin
Chief HR Officer
Dr. Stephen K. Brannan
Chief Medical Officer
Dr. Ronald N. Marcus M.D.
Senior Vice President of Medical
Mr. William Meury
Pres, Chief Executive Officer & Director
Mr. William P. Kane Jr.
Chief Commercial Officer
Ms. Mia Kelley J.D.
Vice President of Legal Affairs
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor
Ms. Stephanie Moore
Vice President of HR
Dr. Andrew Craig Miller
Co-Founder & Chief Operating Officer

How KRTX did perform over past 52-week?

KRTX's closing price is 108.26% higher than its 52-week low of $158.38 where as its distance from 52-week high of $329.99 is -0.05%.

How many employees does KRTX have?

Number of KRTX employees currently stands at 339.

Link for KRTX official website?

Official Website of KRTX is: https://www.karunatx.com

How do I contact KRTX?

KRTX could be contacted at phone 857 449 2244 and can also be accessed through its website. KRTX operates from 99 High Street, Boston, MA 02110, United States.

How many shares of KRTX are traded daily?

KRTX stock volume for the day was 1.28M shares. The average number of KRTX shares traded daily for last 3 months was 971.83K.

What is the market cap of KRTX currently?

The market value of KRTX currently stands at $12.60B with its latest stock price at $329.83 and 38.2M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	339
Beta	1.15
Sales or Revenue	$654.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KRTX Company Profile and Key Details

Karuna Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics